Should You Invest in Ozempic Maker Novo Nordisk in 2026?

The FDA approved a daily oral formulation of Wegovy (semaglutide), the first oral GLP‑1 obesity drug, with phase 3 data showing mean weight loss of 16.6% over 64 weeks and ~33% of patients losing ≥20%. Novo Nordisk will launch the pill in early January with management saying supply is sufficient, a development that helped shares rally after a 40% YTD drop in 2025 amid competition and leadership changes. The company still reported double‑digit revenue growth in its latest quarter, EPS roughly doubled since early 2023, trades at ~13x expected 2025 earnings and yields ~3.3%; analysts argue broader adoption of the pill could reaccelerate top‑line growth by mid‑2026 and justify a re‑rating toward ~20x EPS, implying more than 50% upside on current prices.

Analysis

Market structure: Novo Nordisk (NVO) is the direct beneficiary — oral Wegovy removes a key patient friction (injections) and could expand the addressable obesity market by an estimated 20–30% over 12–24 months versus injectable-only adoption, supporting faster revenue re-acceleration by mid-2026. Losers: telehealth/compounded semaglutide sellers and incumbents relying on injectables will see share loss; Eli Lilly (LLY) faces a narrower window despite its scale because NVO is first-to-market for an oral GLP‑1. Pricing power should improve versus compounding competition but will be constrained by payer negotiation and potential step therapy rules.

Risk assessment: Key tail risks include a payer coverage squeeze or prior‑authorization cascade that limits uptake (could shave 30–50% off peak sales scenarios), an unexpected safety signal or manufacturing disruption (supply issues could delay the mid‑2026 revenue inflection), and faster-than-expected LLY approval (guidance indicates possible March filing). Time horizons: immediate (days) — short-term sentiment pop already priced; short-term (weeks–months) — launch execution and formulary placements; long-term (quarters–years) — sustainable top-line growth and margin recovery. Hidden dependencies: reimbursement timelines, U.S. PBM negotiations, and international pricing dynamics (DKK/FX pass-through) will materially alter realized revenue.

Trade implications: Tactical: establish a modest 2–3% long position in NVO now to capture the January launch momentum and tax‑efficient dividend yield, and add up to a total 4% if NVO retraces >10% from entry or if 1Q US script growth >+30% sequentially. Options: buy a 9–15 month bull call spread (limit cost and vega) to capture mid‑2026 re‑rating — e.g., call debit spread approximately 20%–35% OTM depending on premiums — or sell short-dated covered calls to monetize near-term elevated IV. Pair trade: consider long NVO vs short LLY (1:1 notional) for 6–12 months to isolate first‑mover premium, unwind if LLY approval occurs earlier than March or if NVO misses supply targets.

Contrarian angles: Consensus underestimates payer resistance and the stickiness of compounded alternatives; the market may be underpricing the risk that formulary placement takes 6–12 months, delaying re‑rating. Conversely, the current ~13x 2025 P/E implies >50% upside if NVO sustains ≥15% annual EPS growth — the mispricing is in timing, not direction. Historical parallel: rapid GLP‑1 uptake (Ozempic) drove quick re‑rating then payer countermeasures; expect similar waves here, so cap position size to avoid binary downside from coverage constraints or regulatory surprises.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) immediately to capture the January oral Wegovy launch; add to a 4% total position if shares retrace >10% or if U.S. weekly scripts reported by mid‑Q1 2026 exceed +30% sequential growth.
• Buy a 9–15 month NVO bull call spread (limit debit) roughly 20–35% OTM to profit from a mid‑2026 re‑rating while capping premium exposure; target a 50–100% return or close if implied volatility rises >40% above 30‑day average.
• Initiate a 1:1 pair trade long NVO / short LLY (Eli Lilly) for 6–12 months to capture first‑mover oral advantage; unwind immediately if LLY receives U.S. approval before end of Q1 2026 or if NVO announces supply shortfall.
• Reduce exposure to telehealth/compounded semaglutide providers (private or small‑cap retail chains) by 30–50% within 30 days; these names face demand compression once payers tighten prior‑authorization and defaults to branded oral.
• Monitor three 30–90 day catalysts before scaling: (1) PBM/formulary decisions (national formulary inclusion), (2) weekly U.S. prescription volumes for oral Wegovy in January–March 2026, and (3) any FDA safety communications; trim NVO by 50% if two of these show negative signals (lack of formulary access or safety flags).